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ABSTRACT
Objective: The objective of present study deals with an attempt to formulate Glimepiride in liposomal drug delivery system, in order to maintain 
steady state plasma concentration; hence it has to be administered frequently to the patients, because of its short plasma half life. To maintain steady 
plasma concentration for longer period of time formulation of controlled drug release system is essential. Liposomal drug delivery system provides 
sustained release of Glimepiride.
Methods: Glimepiride liposomes were prepared by ethanol injection method using varying concentration of cholesterol and lecithin. Drug excipient 
compatibility study was performed by FT-IR spectral studies and differential scanning calorimetry studies. Liposomes were evaluated for drug 
encapsulation efficiency, morphological study by optical microscope, SEM and TEM, vesicle size and zeta potential determination, In -vitro drug 
release & kinetic study and stability studies.
Results: The formulations fulfilled all official requirements. The drug release was slow and sustained for >12 hrs. The formulations followed zero 
order kinetics. Zeta potential and stability study for 90 days demonstrated that the formulation was stable at 25¬¬¬¬oC than when refrigerated.
Conclusion: Glimepiride was formulated as liposomal formulation after checking the compatibility by DSC and FT-IR studies. The liposomes 
preparation FA3 was optimized based on the particle size, zeta potential, entrapment efficiency, and drug release characteristics.
Keywords: Liposomes, Antidiabetic, Glimepiride, Ethanol-injection method.
INTRODUCTION
Liposomes are small artificial vesicles of spherical shape 
that can be created from cholesterol and natural nontoxic 
phospholipids [1-3]. Depending on the nature of the drugs, 
liposomes have one or more phospholipid bilayers, to transport drug 
materials [4]. The particle size of liposomes varies from 30 nm to 
several micrometers [5,6]. Liposomes help in increasing the therapeutic 
index of the administered drugs [7]. In liposome formulations, water 
soluble and insoluble materials can be used together without the use of 
surfactants and emulsifiers.
Glimepiride, a third generation sulfonyl urea drug is commonly 
prescribed for diabetic patients with type 2 diabetes mellitus. It lowers 
blood sugar by stimulating the release of insulin by pancreatic beta cells 
and by inducing increased activity of intracellular insulin receptors. 
Considering the solubility, it has no practical solubility in water 
(<0.004 mg/mL). The main factor which affects the bioavailability 
of drugs is patient noncompliance due to frequent administration 
of dosage forms [8-12]. Sustained release formulation scan helps in 
overcoming this problem by its one daily dosing. The dosage schedule 
and pharmacokinetics help in the formulation of sustained release 
dosage form, liposomes. Hence, the study has been focused on the 
formulation and in vitro evaluation of glimepiride-loaded liposomes by 
modified ethanol injection method.
METHODS
Glimepiride was procured from Krebs Healthcare Pvt. Ltd. Soya 
phospholipids and Tween-80 were purchased from HiMedia 
Laboratories Pvt. Ltd. Cholesterol was purchased from Mumbai Thomas 
Bakers Chemical Ltd. All the other ingredients used are of analytical 
grade. The method applied for the formulation of liposomes was 
modified ethanol injection method.
Preformulation studies
Preformulation studies were performed for physical appearance, 
solubility, melting point, and drug-polymer compatibility studies. 
The physical appearance of the drug was noted by visual observation. 
Solubility studies were performed in thoroughly cleaned and dried 
volumetric flask using different investigative solvents and the drug 
concentration was determined spectrophotometrically [1]. Melting 
point determination of glimepiride was determined by using the 
melting point apparatus. Drug-polymer compatibility studies were 
studied using differential scanning calorimetry (DSC) and Fourier 
transform-infrared spectroscopy (FT-IR) studies. The results did not 
show any drug-polymer interaction.
Preparation of glimepiride-loaded liposomes
As the drug is soluble in ethanol, a modified ethanol injection is used 
to prepare glimepiride-loaded liposomes. The required amounts of 
soybean phospholipids, Tween-80 and cholesterol were dissolved 
in ethanol. The resulting organic phase was gently injected to the 
55±2°C aqueous phase under magnetic stirring. Spontaneous liposome 
formation occurred as soon as ethanolic solution was in contact with 
the aqueous phase (phosphate buffered saline, pH 7.0). The liposome 
suspension was then kept under stirring for at room temperature to 
remove the traces of solvent [13].
Characterization of liposomal formulations
Drug encapsulation efficiency
The percentage of drug encapsulated was determined after lysis of 
the prepared liposomes with absolute alcohol and sonication for 
10 minutes. The concentration of drug, glimepiride, in absolute alcohol 
was determined spectrophotometrically at 227 nm using an ultraviolet 
(UV)-visible spectrophotometer (model UV-1700 (E); Shimadzu, 
Kyoto, Japan) in triplicate. The encapsulation efficiency expressed 
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as entrapment percentage was calculated through the following 
relationship [14-16].
% Encapsulation efficiency total drug free drug/total drug×100.
Dynamic light scattering: Vesicle size and zeta potential 
determination
The average diameter of liposomes was determined by dynamic light 
scattering using the photon correlation spectroscopy (PCS) technique. 
The measurements were performed at 25°C using either a Zeta Sizer 4 
(Malvern Instruments, Worcestershire, UK) equipped with a He-Ne gas 
laser (k=0.633 Am) or a Zeta Plus (Brookhaven Instrument Corporation, 
USA). Brookhaven or Malvern PCS software (version 1.52), depending 
on the system, was used for data acquisition and analysis. Polystyrene 
size standards 220T6 nm (Duke scientific corp., Duke, NC) was used to 
verify the performance of the instrument. For viscosity and refractive 
index, the values of pure water were used (1.0). The samples were 
diluted with 10 mM Tris-buffer at pH 7.4 to achieve the optimal vesicle 
concentration. Surface charge on the vesicles was measured indirectly 
via analysis of zeta potential at 25°C using a ZetaPlus instrument 
(Brookhaven Instrument Corporation, USA) in a 1/10 solution of 10 
mM Tris-buffer [17].
Turbidity measurement
The liposomes were diluted with distilled water to give a total 
lipid concentration of 0.312 mM. After rapid mixing by sonication 
for 5 minutes, the turbidity was measured as the absorbance at 




Multilamellar vesicles after dilution with 5% mannitol were viewed 
under optical microscope (Olympus BHA, Japan) to observe the 
shape and lamellar nature of vesicles. Photomicrographs were 
prepared by a camera attached to the optical microscope in 10 × 100 
magnifications [20].
Scanning electron microscopy (SEM)
The morphology (shape and surface characteristics) of liposomes was 
studied by SEM (model JSM-5610LV scanning microscope; Jeol, Tokyo, 
Japan). The sputtering was done for nearly 5 minutes to obtain uniform 
coating on the sample to enable good quality SEM images. The SEM was 
operated at low accelerating voltage of about 15 kV with load current 
of about 80 mA. The condenser lens position was maintained between 
4.4 and 5.1. The objective lens aperture has a diameter of 240 μ and the 
working distance=39 mM [20].
Transmission electron microscopy (TEM)
Drug-loaded liposomes were observed by TEM using a JEM 1010®, 
Jeol (USA). Liposomal dispersion (500 µL) was diluted with phosphate 
buffer and stabilized with glutaraldehyde 2.75%. The samples were 
prepared by placing the diluted liposomes onto a 400-mesh grid coated 
with carbon film. TEM images were analyzed using the soft-imaging 
software ImageJ® (measurement included 100 liposomes) [21].
In vitro drug release and kinetic study
In vitro release of the prepared formulations was evaluated using a 
dynamic dialysis method. The release rate of drug was determined after 
separation of free drug from drug-loaded liposomes by placing it in 
dialysis tubing (10,000 MWCO, Millipore, Boston, USA) and exhaustively 
dialyzed for 15 minutes for several times, each time against 100 mL of 
phosphate buffer (pH 7.4). The dialysis of free drugs was completed after 
1 hr after which no further drug could be detected in the solution. The 
dialyzed suspension containing the drug or plain drug aqueous solution 
was sealed in a dialysis bag (10,000 MWCO, Millipore, Boston, USA). The 
dialysis bag was then immersed in 100 mL of phosphate buffer (pH 7.4) 
thermostatically maintained at 37±0.5°C and magnetically stirred at 
50 rpm. The samples (1 mL) were withdrawn at various time intervals 
and analyzed by a UV spectrophotometer at respective nm. Volumes 
lost by sample withdrawal were replaced with fresh medium. The 
experiments were conducted in triplicate [22].
The data of in vitro release from various liposomes were evaluated 
kinetically using various mathematical models like zero-order, first-
order, Higuchi and Korsmeyer–Peppas model equations.
Stability studies
Physical stability study of the prepared liposomes was carried out 
to determine the comparative leakage of the drug from liposomes 
stored at different conditions compared to each other. After washing 
and removal of the free drug, each liposomal formulation was stored 
either at 4°C or at 25°C. At predetermined time intervals of 15, 30, 60 




Entrapment efficiency was studied for all the 9 formulations to find the 
best, in terms of entrapment efficiency. The encapsulation efficacy was 
obtained as the mass ratio between the amount of the drug incorporated 
in liposomes and this ratio was used in the liposome preparation. There 
are reports that entrapment efficiency was increased, with increasing 
cholesterol content and by the usage of Tween-80 which has higher 
phase transition temperature. By inspection of Table 1, it is obvious that 
glimepiride-encapsulation efficiency had higher values in formulation 
formative assessment (FA) 3.
Dynamic light scattering: Vesicle size and zeta potential 
determination
Zeta potential is a key factor to evaluate the stability of colloidal 
dispersion. In general, particles could be dispersed stably when 
absolute value of zeta potential was above −30 mV due to the electric 
repulsion between particles. Nonionic surfactant could not ionize into 
charging group like ionic, but demonstrated its zeta potential, the 
reason might be due to molecular polarization and the adsorption 
of emulsifier molecule on the charge in water, it was absorbed to the 
emulsifier layer of particle/water interface and electric double layer 
similar to ionic was formed. The results have been mentioned in 
Table 1.
Morphological study
The images confirmed that liposomes were spherical and smooth 
in nature. Therefore, it seems that encapsulation of drug did not 
affect the morphology of liposomes. The TEM study demonstrated 
that the particles had almost spherical and uniform shapes and did 
not stick to each other TEM confirmed the formation of liposomes. 
The morphological images have been shown in Figs. 1-3 of optical 
microscopy, SEM and TEM.









FA 1 82.42±2.45 −19.6±3.8 215.24±8.32 123±2.3
FA 2 92.62±2.37 −17.8±2.6 320.66±10.18 183±2.2 
FA 3 97.55±2.59 −17.6±3.2 115.78±9.31 219±3.2
FA 4 89.71±2.31 −16.6±2.8 105.82±3.26 194±2.4
FA 5 88.54±2.32 −15.4±3.8 103.02±6.26 230±5.2
FA 6 79.60±2.19 −14.6±2.4 140.12±12.18 202±3.2
FA 7 89.25±2.21 −15.6±2.6 99.56±9.31 192±4.2
FA 8 85.35±2.52 −15.4±2.8 205.12±9.27 169±2.5
FA 9 89.77±2.43 −17.6±3.2 295.78±9.31 188±3.9
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Fig. 1: Optical microscopic image of the optimized formulations 
formative assessment 3
Fig. 2: Scanning electron microscopic image of the optimized 
formulations formative assessment 3
Fig. 3: Scanning electron microscopic image of the optimized 
formulations formative assessment 3
Fig. 4: In vitro drug release graph formative assessment (FA) 
1-FA 9
Fig. 5: Higuchi’s plot for formative assessment (FA) 1-FA 9
Fig. 6: Peppa’s plot for formative assessment (FA) 1-FA 9
Table 2: Stability studies results at various time intervals
FA 3 Stored at 4°C (in days) Stored at 25°C (in days)
15 30 60 90 15 30 60 90
Encapsulation efficiency (%) 95.23±3.2 92.31±2.4 89.24±1.2 86.23±1.2 97.23±3.2 97.31±2.4 96.24±1.2 95.23±1.2
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Optical microscope
The drug release from glimepiride-liposomes, however, did not show 
significant burst release. The drug was released slower and controlled 
from liposomes. The release of glimepiride from loaded liposomes was 
in accordance with the Zero-order kinetics, Higuchi’s and Peppa’s plot 
which forecast the release amount and mechanism of drug release from 
the liposomes. In vitro drug release studies of the glimepiride-liposomes 
revealed that the glimepiride diffusion drug release from all the 
formulations followed zero-order kinetics (r2-0.952) and ascertained 
by Higuchi’s and Peppas mechanism which reveals that it governed 
by erosion (r2-0.996) and Fickian type (n=0.450) of drug diffusion 
release, respectively. Based on the % drug entrapment efficiency and% 
drug release, formulation FA 3 was considered to be the optimized 
formulations. The percent cumulative amounts of glimepiride released 
as a function of time from liposomes formulated was illustrated as zero-
order, Higuchi’s and Peppa’s plot in Figs.4-6, respectively.
Stability studies
Physical stability study of the prepared liposomes was carried out 
to determine the comparative leakage of the drug from liposomes 
stored at different conditions compared to each other. After washing 
and removal of the free drug, each liposomal formulation was stored 
either at 4°C or at 25°C. At predetermined time intervals of 15, 30, 
60 and 90 days has shown in Table 2. The encapsulation efficiency of 
glimepiride-liposomes was determined.
CONCLUSION
Antidiabetic drug, glimepiride was formulated as liposomal formulation 
after checking the compatibility by DSC and FT-IR studies. The 
liposomes preparation FA 3 was optimized based on the particle size, 
zeta potential, entrapment efficiency, and drug release characteristics. 
Thus, glimepiride when formulated showed sustained release property 
which could be successfully developed as liposomes.
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